Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Breezula's phase 3 enrollment for hair loss treatment is complete, but results have not been published, causing skepticism about its progress. Some users express doubt about its future, suggesting it may be reserved for exclusive use.

Breezula's potential as a hair loss treatment is debated, with some seeing promise despite delays, while others suggest alternatives like Pyrilutamide. Breezula is compared to topical finasteride, with hopes for a better side effect profile.

Breezula/Winlevi's potential use for hair loss is discussed, with concerns about its effectiveness compared to Breezula's higher concentration. Users express interest in a topical treatment with minimal side effects, noting that Breezula's efficacy may decline after six months.

Discussion on hair loss treatments, focusing on Breezula, with mentions of Minoxidil, finasteride, RU58841, Pyrilutamide, GT20029, and PP405. Breezula's effectiveness is uncertain, with some trials showing minimal regrowth.

Breezula (clascoterone) initially performed better than finasteride for hair loss but then effectiveness decreased almost back to baseline after 6 months, raising questions about its strength.

The conversation is about whether it is safe to take Xeljanz, a JAK inhibitor, while also taking finasteride for hair loss. The concern is that Xeljanz weakens the immune system, which could be risky.

Breezula's effectiveness is uncertain, with some users skeptical about its potential and others noting its recent availability on the grey market. A user reported success with a stack of Dutasteride (oral), Minoxidil (topical), and RU58841 (topical), achieving significant hair improvement after 18 months.

The conversation is about using Xeljanz for hair regrowth in individuals with LPP. The user is seeking experiences and expectations from others who have tried this treatment.

Breezula is expected to launch in late 2026, with data being sent to the FDA in early 2026. The process is typical for a successful trial.

Breezula is discussed as a potential topical anti-androgen treatment for hair loss, with mixed opinions on its effectiveness and side effects compared to other treatments like finasteride, minoxidil, and RU58841. Some users express skepticism about its long-term efficacy and potential side effects, while others are hopeful for its approval and use in combination with existing treatments.

Breezula (clascoterone) Phase 3 hair loss trial results are delayed, with no official updates yet. The acne version is approved, but hair loss results are still pending.

SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.

A user experienced issues with an order from Umbrella Labs, initially not receiving their product, PP405, and facing poor customer service, but eventually received the order after posting about it. Other users also reported similar problems with incomplete orders and lack of communication from the company.

A 31-year-old discusses hair loss treatments using topical Minoxidil, finasteride, RU58841, JXL069, and Nizoral. Users note new hair growth and inquire about the source of JXL069.

The user switched from oral minoxidil to topical minoxidil and added JXL-069/PP405-3HP, along with topical dutasteride, melatonin, and tretinoin. They also use low-level laser therapy (LLLT) but doubt its effectiveness.

Deuruxolitinib, combined with two other drugs, shows promise in regrowing significant hair in severe alopecia areata patients. This new treatment approach could become a standard of care, offering hope for those with limited options.

A user with alopecia totalis, borderline universalis, seeks advice on getting into a Xeljanz trial or appealing insurance for coverage. They experienced significant hair regrowth but are now seeing hair loss again and want to try Xeljanz.

The conversation discusses hair loss treatments, specifically Breezula, Minoxidil, finasteride, and RU58841. Participants express curiosity about Breezula's safety and its steroidal nature.

Eucapil, containing fluridil, is used for hair loss but has impractical packaging. Some users find it effective for maintenance, while others suggest alternatives like anageninc with pyrilutamide.